LODENAFIL CARBONATE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C47H62N12O11S2
Molecular Weight	1035.199
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NN(C)C2=C1N=C(NC2=O)C3=CC(=CC=C3OCC)S(=O)(=O)N4CCN(CCOC(=O)OCCN5CCN(CC5)S(=O)(=O)C6=CC=C(OCC)C(=C6)C7=NC8=C(N(C)N=C8CCC)C(=O)N7)CC4

InChI

InChIKey=MVYUCRDXZXLFSB-UHFFFAOYSA-N

InChI=1S/C47H62N12O11S2/c1-7-11-35-39-41(54(5)52-35)45(60)50-43(48-39)33-29-31(13-15-37(33)67-9-3)71(63,64)58-21-17-56(18-22-58)25-27-69-47(62)70-28-26-57-19-23-59(24-20-57)72(65,66)32-14-16-38(68-10-4)34(30-32)44-49-40-36(12-8-2)53-55(6)42(40)46(61)51-44/h13-16,29-30H,7-12,17-28H2,1-6H3,(H,48,50,60)(H,49,51,61)

HIDE SMILES / InChI

Molecular Formula	C47H62N12O11S2
Molecular Weight	1035.199
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18593576 | https://www.ncbi.nlm.nih.gov/pubmed/20214718

Lodenafil carbonate, a novel phosphodiesterase 5 inhibitor developed in Brazil. Lodenafil carbonate is a prodrug that is metabolized with formation of the active compound, lodenafil. Lodenafil carbonate participated in phase III clinical trial for erectile dysfunction and showed a satisfactory efficacy-safety profile.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cGMP-specific 3',5'-cyclic phosphodiesterase 6 Target ID: O76074 Gene ID: 8654.0 Gene Symbol: PDE5A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18593576	Inhibitor 8504

PubMed

Title	Date	PubMed
Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats.	2014-04-13	25210965
Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial.	2010-05	20214718
[Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption].	2010-02	20428608
Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum.	2008-09-04	18593576

Sample Use Guides

In Vivo Use Guide

lodenafil carbonate (LC) 40 mg or LC 80 mg and followed for 4 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:59:08 GMT 2025` Edited by `admin` on `Mon Mar 31 20:59:08 GMT 2025`
Record UNII	29X84F932D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LODENAFIL CARBONATE

Official Name

English

lodenafil carbonate [INN]

Preferred Name

English

7H-PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE, 5,5'-(CARBONYLBIS(OXY-2,1-ETHANEDIYL-4,1-PIPERAZINEDIYLSULFONYL(6-ETHOXY-3,1-PHENYLENE)))BIS(1,6-DIHYDRO-1-METHYL-3-PROPYL-

Common Name

English

Lodenafil Carbonate [WHO-DD]

Common Name

English

BIS(2-(4-(4-ETHOXY-3-(1-METHYL-7-OXO-3-PROPYL-4,7-DIHYDRO-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)PHENYLSULFONYL)PIPERAZIN-1-YL)ETHYL) CARBONATE

Common Name

English

HELLEVA

Brand Name

English

1-PIPERAZINEETHANOL, 4-((3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-, CARBONATE (2:1) (ESTER)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID70192906